The Science Journal of the Lander College of Arts and Sciences
Abstract
Type 2 Diabetes Mellitus is a prevalent metabolic disorder characterized by insulin resistance and pancreatic beta-cell dysfunction, leading to chronic hyperglycemia and comorbidities such as obesity and cardiovascular disease. Traditional treatments focus on glycemic control, but often fail to address the broader spectrum of related conditions. This study investigates the potential of glucagon-like peptide-1 receptor agonists (GLP-1RAs) to combat type 2 diabetes and its comorbidities through their diverse mechanisms of action. GLP-1RAs not only improve glycemic control by enhancing insulin secretion and inhibiting glucagon release, but also promote weight loss, reduce inflammation, and lower cardiovascular risk. The efficacy of GLP-1RAs in achieving these benefits was examined through mechanisms independent of their glucose-lowering effects, such as suppressing appetite in specific brain regions and triggering macrophage phenotype switching. The findings suggest that GLP-1RAs offer a comprehensive approach to managing type 2 diabetes and its associated comorbidities, providing a promising therapeutic avenue that extends beyond standard diabetes medications.
Recommended Citation
Michael Weingarten. (2024). Is it Possible for GLP-1RAs to Combat type 2 Diabetes and its Comorbidities?. The Science Journal of the Lander College of Arts and Sciences, 18(1), 43-49. Retrieved from https://touroscholar.touro.edu/sjlcas/vol18/iss1/8
